NuSep tries NxGen

By Dylan Bushell-Embling
Thursday, 02 October, 2008


Bioseparations company NuSep [ASX: NSP] has reached a binding agreement to acquire NxGen Pharmaceuticals for $25 million.

Pending shareholder approval, NuSep will acquire all of NxGen in exchange for 294 million NuSep shares valued at 8.5c each.

This represents 87.5 per cent of NuSep's expanded capital and 10 times NxGen's net profit forecast for this financial year.

NxGen is a custom pharmaceuticals manufacturer and formulator, with products including an erectile dysfunction nasal spray it makes for a medical clinic.

Related Articles

New species of bacteria discovered in prostate cancer patients

Researchers have discovered the genetic blueprints of 18 new bacterial species in prostate cancer...

Award-winning system automates vial filling for cell therapy

Celleo's Larkem V40 — created to address one of the bottlenecks holding back cell...

Air pollutant exposure linked to glaucoma, cataracts and suicide

People who are exposed to high levels of air pollution are more likely to develop glaucoma and...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd